Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is a heterogeneous disorder that develops as a result of relatively inappropriate insulin secretion often in the setting of defective insulin action (insulin resistance). The factors responsible for insufficient insulin production in patients with type 2 diabetes are complex and are thought to involve a combination of genetic and metabolic defects, including chronic hyperglycemia, increased levels of free fatty acids, and dyslipidemia, which contribute to an inability to sustain adequate insulin secretion, defective β-cell proliferation, and/or increased β-cell apoptosis (1). Studies of the natural history of type 2 diabetes inform us that a progressive decline in β-cell function is common in diabetic patients independent of the method of treatment (2). Hence, new approaches are clearly needed that not only control metabolic abnormalities such as dyslipidemia and hyperglycemia, but that also preserve β-cell function and mass, perhaps by increasing the number of newly formed β-cells and/or decreasing β-cell death. Emerging experimental evidence has confirmed that elevated levels of glucose and specific monounsaturated fatty acids may be deleterious to β-cell survival in short-term studies of human islets (3). Although detailed information about the relative balance of β-cell proliferation and apoptosis in pancreases from subjects with type 2 diabetes is not available, recent autopsy data suggest that a combination of inappropriately decreased β-cell mass and increased β-cell apoptosis in the diabetic pancreas may be more common than previously appreciated (4, 5). Hence, absolute or relative deficiency of β-cells occurs paradoxically at a time when enhanced functional β-cell mass and increased insulin production is needed to overcome insulin resistance. Not surprisingly, the progressive deterioration in β-cell function that accompanies type 2 diabetes has sparked interest in identifying factors that either promote formation of new β-cells or inhibit the death of vulnerable β-cells (1). Experimental studies carried out predominantly in rodents have demonstrated that IGFs, hepatocyte growth factor, pituitary adenylate cyclase-activating polypeptide, PTHrP, epidermal growth factor receptor agonists in combination with gastrin, and incompletely characterized proteins such as islet neogenesis-associated protein, are capable of enhancing β-cell mass in the setting of experimental diabetes. Hence, prolonged administration of these agents may expand β-cell mass, ultimately leading to increased insulin secretion and improved glycemic control. Similarly, growth factors may also expand the number of human islet cells in experimental culture systems (6, 7). Nevertheless, none of these proteins has been demonstrated to rapidly lower blood glucose and improve metabolic control in preclinical models of diabetes independent of their chronic effects on islet proliferation or β-cell survival. Hence, pharmaceutical development of molecules exhibiting β-cell growth factor-like activity that do not concomitantly acutely lower blood glucose remains highly challenging as it may take weeks or more likely months to determine their potential efficacy in diabetic human subjects. New data presented in the article by Farilla et al. (8) in this issue of Endocrinology now demonstrate that glucagon-like peptide-1 (GLP-1), a gut hormone derived from enteroendocrine L cells, inhibits cell death in freshly isolated human islets cultured in vitro for 5 d. The antiapoptotic effects of GLP-1 have previously been demonstrated in diabetic rodents, islet cell lines, purified rat β-cells, and heterologous cells expressing the GLP-1 receptor (9–12). Intriguingly, GLP-1 receptor activation also enhances neuronal survival in diverse cellular and animal models of neuronal toxicity, and elimination of GLP-1 receptor function in mice is associated with increased neurotoxicity after peripheral administration of kainic acid (13, 14). Furthermore, the antiapoptotic actions of GLP-1 are essential for β-cell survival in response to cellular injury, as mice with a disruption of the GLP-1 receptor gene exhibit enhanced β-cell death and more severe hyperglycemia after exposure to streptozotocin (10). Farilla et al. (8) added GLP-1 (10 nm) to human islet cells isolated from three independent donors and observed preserved islet morphology in the GLP-1-treated islets, whereas control islets exhibited a greater degree of degradation and loss of three-dimensional structure. GLP-1 treatment was also associated with reduced morphological features of β-cell apoptosis (nuclear condensation and fragmentation) and decreased expression of active caspase-3, an enzyme that plays an essential role in the final pathway leading to programmed cell death. The authors found that GLP-1-treated islets exhibited a progressive increase in the levels of the prosurvival protein bcl-2, which likely contributed to the antiapoptotic actions of GLP-1 in the islet cultures. GLP-
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It also promotes proliferation and reduces apoptosis of pancreatic β-cells, thereby maintaining their quality and functionality.130,218”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [218]
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 2×
“As GLP-1 treatment of human diabetic subjects improves metabolic control resulting in reduction of hyperglycemia and a decrease in circulating fatty acids (25), GLP-1 may also indirectly attenuate islet glucotoxicity and lipotoxicity, thereby resulting in healthier -cells and reduced -cell death (Fig.”
BackgroundXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Self-citationFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 3×
“glucose-dependent insulin secretion (8).”
BackgroundInfluentialSelective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 2×
“glycemia after exposure to streptozotocin (10).”
BackgroundSelf-citationEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Self-citation
Cited by
Items 101–200 of 281
Mechanism of the beneficial and protective effects of exenatide in diabetic rats
Lotfy, M. A., Singh, J., Rashed, H., Tariq, S., Zilahi, E., & Adeghate, E. A. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0426 · Cited by 51
Role of the incretin system in the remission of type 2 diabetes following bariatric surgery
Mingrone, G. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.07.004 · Cited by 56
Diabetes mellitus and gastric emptying: questions and issues in clinical practice
Samsom, M., Bharucha, A., Gerich, J. E., Herrmann, K., Limmer, J., Linke, R., Maggs, D., Schirra, J., Vella, A., Wörle, H., et al. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.974 · Cited by 48
Jelsing, J., Vrang, N., van Witteloostuijn, S. B., Mark, M., & Klein, T. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0479 · Cited by 52
Cozar-Castellano, I., Haught, M., & Stewart, A. F. (2006) · Diabetes · doi:10.2337/db06-0627 · Cited by 47
Karunakaran, U., Kim, H., Kim, J.-Y., & Lee, I. (2011) · Experimental Diabetes Research · doi:10.1155/2012/639762 · Cited by 53
Bollyky, P. L., Bice, J. B., Sweet, I. R., Falk, B. A., Gebe, J. A., Clark, A., Gersuk, V. H., Aderem, A. A., Hawn, T. R., & Nepom, G. T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005063 · Cited by 48
Phosphoproteins in Stress-Induced Disease
Dalton, L. E., Healey, E., Irving, J. A., & Marciniak, S. J. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-396456-4.00003-1 · Cited by 52
Holz, G. G., & Chepurny, O. G. (2005) · Science's STKE · doi:10.1126/stke.2682005pe2 · Cited by 45
DPP-4 Inhibitors in Clinical Practice
Palalau, A. I., Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2079 · Cited by 44
Souza‐Mello, V., Gregório, B. M., Lucas, B. R., Faria, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2011) · Pancreas · doi:10.1097/mpa.0b013e3182153922 · Cited by 45
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A. (2021) · Medicina · doi:10.3390/medicina57070669 · Cited by 43
Liu, M.-J., Shin, S., Li, N., Shigihara, T., Lee, Y.-S., Yoon, J., & Jun, H. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300005 · Cited by 44
Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease
Lv, D., Feng, P., Guan, X., Liu, Z., Li, D., Xue, C., Bai, B., & Hölscher, C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1462240 · Cited by 49
Bonora, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01441.x · Cited by 43
Sinclair, E. M., & Drucker, D. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000155379.11926.e2 · Cited by 39
Self-citationNutraceutical Properties of Camel Milk
Alavi, F., Salami, M., Emam‐Djomeh, Z., & Mohammadian, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809762-5.00036-x · Cited by 40
Heo, C. U., & Choi, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030393 · Cited by 43
Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review
Noh, R. M., Graveling, A. J., & Frier, B. M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.589835 · Cited by 36
Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes
Maggs, D. G., Macdonald, I. A., & Nauck, M. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00737.x · Cited by 40
Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus
Pok, E.-H., & Lee, W.-J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14315 · Cited by 40
Update on the Protective Molecular Pathways Improving Pancreatic Beta-Cell Dysfunction
Puddu, A., Sanguineti, R., Mach, F., Dallegri, F., Viviani, G. L., & Montecucco, F. (2013) · Mediators of Inflammation · doi:10.1155/2013/750540 · Cited by 35
Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
Cheng, Q., Cheng, J., Cordato, D. J., & Gao, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107559 · Cited by 33
Impact of Gastric Bypass Surgery on Gut Hormones and Glucose Homeostasis in Type 2 Diabetes
Näslund, E. B., & Kral, J. G. (2006) · Diabetes · doi:10.2337/db06-s012 · Cited by 36
Kim, J. Y., Kim, M., Kim, K., Song, K. B., Lee, S. H., Hwang, D. W., Kim, K., Kim, H. J., Yu, E., Kim, S. C., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000383 · Cited by 33
Berberine chloride improved synaptic plasticity in STZ induced diabetic rats
Moghaddam, H. K., Baluchnejadmojarad, T., Roghani, M., Goshadrou, F., & Ronaghi, A. (2013) · Metabolic Brain Disease · doi:10.1007/s11011-013-9411-5 · Cited by 31
Shimizu, H., Eldar, S. M., Heneghan, H., Schauer, P. R., Kirwan, J. P., & Brethauer, S. A. (2013) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2013.01.021 · Cited by 31
Kassem, M. A. M., Durda, M. A., Stoicea, N., Cavus, O., Sahin, L., & Rogers, B. M. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00037 · Cited by 38
Bakbak, E., Terenzi, D. C., Trac, J. Z., Teoh, H., Quan, A., Glazer, S. A., Rotstein, O. D., Al-Omran, M. A., Verma, S., & Hess, D. A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09669-7 · Cited by 32
Tilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 32
Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension
Liu, L., Liu, J., & Huang, Y. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000176 · Cited by 32
Vermeulen, M. A. R., Richir, M. C., Garretsen, M. K., van Schie, A., Ghatei, M. A., Holst, J. J., Heijboer, A. C., Uitdehaag, B. M. J., Diamant, M., Eekhoff, E. M. W., et al. (2011) · Nutrition · doi:10.1016/j.nut.2010.10.001 · Cited by 32
Razny, U., Kiec-Wilk, B., Polus, A., Goralska, J., Malczewska-Malec, M., Wnek, D., Zdzienicka, A., Gruca, A., Childs, C. E., Kapusta, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.05.001 · Cited by 27
“Glucose-dependent 74 insulinotropic polypeptide (GIP) is released from enteroendocrine K cells in response 75 to oral ingestion of fat or glucose [6] and stimulates insulin secretion from pancreatic 76 β-cells in a glucose-dependent manner [7].”
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 30
Zheng, Y.-C., He, H., Wei, X., Ge, S., & Lü, Y. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b03845 · Cited by 28
Araj‐Khodaei, M., Ayati, M. H., Azizi-Zeinalhajlou, A., Novinbahador, T., Yousefi, M., Shiri, M., Mahmoodpoor, A., Shamekh, A., Namazi, N., & Sanaie, S. (2023) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2023.2258559 · Cited by 34
QSAR study of dipeptidyl peptidase-4 inhibitors based on the Monte Carlo method
Sokolovic, D. T., Ranković, J., Stanković, V., Stefanović, R., Karaleić, S., Mekić, B. B., Milenković, V., Kocić, J., & Veselinović, A. M. (2017) · Medicinal Chemistry Research · doi:10.1007/s00044-017-1792-2 · Cited by 26
Ghanaat‐Pour, H., & Sjöholm, Å. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.896 · Cited by 28
Preservation of Beta-Cell Function in Type 2 Diabetes
Nyalakonda, K., Sharma, T., & Ismail‐Beigi, F. (2010) · Endocrine Practice · doi:10.4158/ep10112.ra · Cited by 27
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.10.1705 · Cited by 25
Xie, Y., Wang, S., Wei-wei, S. H. A., Zhou, X., Wang, W., Li-pin, H. A. N., Li, D., & Demin, Y. (2008) · Chinese Medical Journal · doi:10.1097/00029330-200811010-00005 · Cited by 24
Exenatide once weekly: clinical outcomes and patient satisfaction
Tahrani, A. A., Jose, B., Piya, M. K., & Barnett, A. H. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s7494 · Cited by 28
Timper, K., Grisouard, J., Radimerski, T., Dembinski, K., Peterli, R., Häring, A., Frey, D. M., Zulewski, H., Keller, U. B., Müller-Stich, B. P., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1324 · Cited by 27
Evaluation and management of ketosis-prone diabetes
Gaba, R., Mehta, P. B., & Balasubramanyam, A. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1561270 · Cited by 23
Cases, A. I., Ohtsuka, T., Fujino, M., Ideno, N., Kozono, S., Zhao, M., Ohuchida, K., Aishima, S., Nomura, M., Oda, Y., et al. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182a71537 · Cited by 26
The impact of obesity on diabetes mellitus and the role of bariatric surgery
Gill, R. S., Sharma, A. M., Gill, S. S., Birch, D. W., & Karmali, S. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.03.020 · Cited by 25
Freeman, J. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0467 · Cited by 24
Andrews, K., Beebe, D. A., Benbow, J. W., Boyer, D. A., Doran, S. D., Hui, Y., Liu, S., McPherson, R. K., Neagu, C., Parker, J. C., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.055 · Cited by 21
Treating Type 2 Diabetes Mellitus With Sleeve Gastrectomy in Obese Patients
Gill, R. S., Karmali, S., & Sharma, A. M. (2010) · Obesity · doi:10.1038/oby.2010.261 · Cited by 23
Insulin improves β-cell function in glucose-intolerant rat models induced by feeding a high-fat diet
Li, H., Wang, B., Deng, X., Zhang, J., Wang, Y., Zheng, J., Xia, W., Zeng, T., & Chen, L. (2011) · Metabolism · doi:10.1016/j.metabol.2011.01.018 · Cited by 21
Ece, İ., Yılmaz, H., Yormaz, S., Çolak, B., Çalışır, A., & Şahin, M. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05212-w · Cited by 26
EXtENDINg β cell survival by UPRegulating ATF4 translation
Wek, R. C., & Anthony, T. G. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.006 · Cited by 22
Zhu, Y., Xia, S., Zhu, M., Yi, W., Cheng, J., Song, G., Li, Z., & Lü, P. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.08.002 · Cited by 20
Deniz, M., Atasoy, B. M., Dane, F., Can, G., Erzık, C., Çetınel, Ş., & Yeğen, B. Ç. (2015) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2015.01.010 · Cited by 22
Campos, J. M., RAMOS, A. C., SZEGO, T., Zilberstein, B., Neto, H. F. E. C., & COHEN, R. V. (2016) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-6720201600s10025 · Cited by 25
Owolabi, B. O., Musale, V., Ojo, O. O., Moffett, R. C., McGahon, M. K., Curtis, T. M., Conlon, J. M., Flatt, P. R., & Abdel‐Wahab, Y. H. A. (2017) · Biochimie · doi:10.1016/j.biochi.2017.04.004 · Cited by 22
Kim, D.-M., Chu, S.-H., Kim, S., Park, Y.-W., & Kim, S.-S. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.4.212 · Cited by 18
Ma, X., Hui, H., Liu, Z., He, G., Hu, J. R., Meng, J., Guan, L., & Luo, X. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01070.x · Cited by 18
An update on pancreatic regeneration mechanisms: Searching for paths to a cure for type 2 diabetes
Soldovieri, L., Giuseppe, G. D., Ciccarelli, G., Quero, G., Cinti, F., Brunetti, M., Nista, E. C., Gasbarrini, A., Alfieri, S., Pontecorvi, A., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101754 · Cited by 20
Hepatic electrical stimulation reduces blood glucose in diabetic rats
Chen, J., Pasricha, P. J., Yin, J., Li, L., & Chen, J. D. Z. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01556.x · Cited by 18
DPP‐4 inhibition and islet function
Åhrén, B. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00184.x · Cited by 16
Barakat, G. M., Moustafa, M. E., & Bikhazi, A. B. (2012) · Biochemical Genetics · doi:10.1007/s10528-012-9532-2 · Cited by 19
The EP3 Receptor/Gz Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease
Schaid, M. D., Wisinski, J. A., & Kimple, M. E. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0097-1 · Cited by 16
3D-QSAR studies of dipeptidyl peptidase-4 inhibitors using various alignment methods
Patel, B., & Ghate, M. D. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1178-7 · Cited by 17
Sporadically occurring functional pancreatic endocrine tumors: review of recent literature
Goldin, S. B., Aston, J., & Wahi, M. M. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f290af · Cited by 18
Kuhadiya, N. D., Prohaska, B. D., Ghanim, H., & Dandona, P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13609 · Cited by 19
Pbx1 is a co-factor for Cdx-2 in regulating proglucagon gene expression in pancreatic A cells
Liu, T., Branch, D. R., & Jin, T. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.02.007 · Cited by 21
Gao, H., Zhao, Q., Song, Z., Yang, Z., Wu, Y., Tang, S., Alahdal, M., Zhang, Y., & Jin, L. (2017) · The FASEB Journal · doi:10.1096/fj.201700002r · Cited by 15
Vedtofte, L., Bödvarsdóttir, T., Gotfredsen, C. F., Karlsen, A. E., Knudsen, L. B., & Heller, R. S. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.12.005 · Cited by 17
In Vivo Regeneration of Insulin-Producing β-Cells
Jun, H. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_27 · Cited by 16
Bohman, S., Waern, I., Andersson, A., & King, A. (2007) · Cell Transplantation · doi:10.3727/000000007783464452 · Cited by 16
Mitochondrial signal transduction in pancreatic β-cells
Maechler, P. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.07.003 · Cited by 16
Saghahazrati, S., Ayatollahi, S. A., Kobarfard, F., & Zangii, B. M. (2020) · PubMed Central · doi:10.22074/cellj.2020.6325 · Cited by 13
The latest pharmacotherapy options for type 1 diabetes
Ludvigsson, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.855197 · Cited by 13
New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus
Raman, V. S., & Heptulla, R. A. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181975ee4 · Cited by 13
Sulfonilureas en el tratamiento del paciente con diabetes mellitus tipo 2
Sánchez, L. F. P. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)76259-4 · Cited by 18
Tsurutani, Y., Omura, M., Matsuzawa, Y., Saito, J., Higa, M., Taniyama, M., & Nishikawa, T. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2016.12.002 · Cited by 13
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
Schwartz, S. S. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s11389 · Cited by 17
Shen, W.-R., Kitaura, H., Qi, J., Ogawa, S., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Pramusita, A., & Mizoguchi, I. (2020) · The Angle Orthodontist · doi:10.2319/021320-103.1 · Cited by 19
Oliveira, J. A. P., Camacho-Ramírez, A., Salas-Alvarez, J., Campos-Martinez, F. J., Lechuga-Sancho, A. M., Gomar, D. A., Blandino-Rosano, M., & Pérez-Arana, G.-M. (2019) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2019.01.007 · Cited by 13
Pathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., John‐Kalarickal, J., & Fonseca, V. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_13 · Cited by 15
Boer, G. A., Hunt, J. E., Gabe, M. B. N., Windeløv, J. A., Sparre‐Ulrich, A. H., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15894 · Cited by 13
Cirurgia gastrointestinal no tratamento da diabete tipo 2
de Freitas, A. C. T. (2007) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/s0102-67202007000200012 · Cited by 14
The main participation of the enterohormone GLP-1 after bariatric surgery
Moreno-Arciniegas, A., Falckenheiner-Soria, J., Reyes, J. B.-D. L., Camacho-Ramírez, A., Mayo-Ossorio, M. A., Pacheco-García, J. M., Pérez-Arana, G.-M., & Oliveira, J. A. P. (2019) · Minerva Chirurgica · doi:10.23736/s0026-4733.18.07681-2 · Cited by 11
Khan, M. I., & Weinstock, R. S. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00016-6 · Cited by 28
Effect of glucagon‐like peptide‐1 gene expression on graft function in mouse islet transplantation
Chae, H., Kang, J., Kim, C., Lee, S.-J., Lee, M., Kang, D., Jun, H., & Ihm, S. (2012) · Transplant International · doi:10.1111/j.1432-2277.2011.01394.x · Cited by 11
ASP4000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity
Tanaka‐Amino, K., Matsumoto, K., Hatakeyama, Y., Shima, I., Takakura, S., & Muto, S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.05.034 · Cited by 12
Jiang, D., & Wan, F. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6240 · Cited by 15
Therapeutic intervention in the GLP‐1 pathway in Type 2 diabetes
Lévy, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01833e.x · Cited by 9
Campos, J. M., RAMOS, A. C., SZEGO, T., Zilberstein, B., Neto, H. F. E. C., & COHEN, R. V. (2016) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-67202016nahead0001 · Cited by 16
Reprogramming—Evolving Path to Functional Surrogate β-Cells
Kalo, E., Read, S. A., & Ahlenstiel, G. (2022) · Cells · doi:10.3390/cells11182813 · Cited by 13
Wang, P., Hill, T. A., Mitchell, J. M., Fitzsimmons, R. L., Xu, W., Loh, Z., Suen, J. Y., Lim, J., Iyer, A., & Fairlie, D. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00653 · Cited by 8
Jacenik, D., Lebish, E. J., & Beswick, E. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113561 · Cited by 8
Durable remission of diabetes after bariatric surgery: What is the underlying pathway?
Wilson, J. B., & Pories, W. J. (2010) · Insulin · doi:10.1016/s1557-0843(10)80009-0 · Cited by 11
McDaniel, M. L. (2010) · The Open Endocrinology Journal · doi:10.2174/1874216501004010040 · Cited by 9
Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of Type 2 diabetes
Benbow, J. W., Andrews, K., Aubrecht, J., Beebe, D. A., Boyer, D. D., Doran, S. D., Homiski, M. L., Hui, Y., McPherson, K., Parker, J. C., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.02.099 · Cited by 8
Boada, C. A. C., & Martínez-Moreno, J. M. (2013) · PubMed · doi:10.3305/nh.2013.28.sup2.6707 · Cited by 11
The critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes
Chen, J., Dong, X., Lin, Y., & Lv, C. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155985 · Cited by 7
Patel, R., Kokori, E., Olatunji, G. D., Adejumo, F. A., Ukah, J. D., Babalola, A. E., Ndakotsu, A., Abraham, I. C., & Aderinto, N. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00704-1 · Cited by 10
Irace, C., Rossetti, M., Carallo, C., Morano, S., Vespertini, V., Mandosi, E., Maranghi, M., Fiorentino, R., Filetti, S., & Gnasso, A. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0261-5 · Cited by 7
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Drucker, Daniel J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2003-12-01
- Volume
- 144
- Issue
- 12
- Pages
- 5145-5148
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2141880555
- Cited by
- 274
- References
- 39
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 7 · 2023: 3 · 2022: 9 · 2021: 8 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 12 · 2016: 10 · 2015: 6 · 2014: 10 · 2013: 18 · 2012: 7
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- glucagon-like peptide-1, beta-cell proliferation, beta-cell apoptosis, type 2 diabetes, beta-cell mass, islet neogenesis, insulin secretion, insulin resistance, growth factors, islet transplantation, beta-cell preservation, monounsaturated fatty acids, hyperglycemia, parathyroid hormone-related protein, gastrin
- MeSH terms
- Animals, Cell Division, Glucagon, Humans, Islets of Langerhans, Peptide Fragments, Protein Precursors, Apoptosis, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.